Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis.
Identifieur interne : 000036 ( Ncbi/Merge ); précédent : 000035; suivant : 000037Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis.
Auteurs : S. Paramothayan ; T. Lasserson ; E H WaltersSource :
- The Cochrane database of systematic reviews [ 1469-493X ] ; 2003.
Descripteurs français
- KwdFr :
- Antinéoplasiques (effets indésirables), Antinéoplasiques (usage thérapeutique), Chloroquine (usage thérapeutique), Ciclosporine (usage thérapeutique), Essais contrôlés randomisés comme sujet, Humains, Immunosuppresseurs (effets indésirables), Immunosuppresseurs (usage thérapeutique), Méthotrexate (usage thérapeutique), Sarcoïdose pulmonaire (traitement médicamenteux).
- MESH :
- effets indésirables : Antinéoplasiques, Immunosuppresseurs.
- traitement médicamenteux : Sarcoïdose pulmonaire.
- usage thérapeutique : Antinéoplasiques, Chloroquine, Ciclosporine, Immunosuppresseurs, Méthotrexate.
- Essais contrôlés randomisés comme sujet, Humains.
English descriptors
- KwdEn :
- Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Chloroquine (therapeutic use), Cyclosporine (therapeutic use), Humans, Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Methotrexate (therapeutic use), Randomized Controlled Trials as Topic, Sarcoidosis, Pulmonary (drug therapy).
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Immunosuppressive Agents.
- chemical , therapeutic use : Antineoplastic Agents, Chloroquine, Cyclosporine, Immunosuppressive Agents, Methotrexate.
- drug therapy : Sarcoidosis, Pulmonary.
- Humans, Randomized Controlled Trials as Topic.
Abstract
Immunosuppressive and cytotoxic agents have been used as both an alternative to oral corticosteroids, and as a means of maintaining a low dose of steroids in the treatment of pulmonary sarcoidosis.
DOI: 10.1002/14651858.CD003536
PubMed: 12917971
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000462
- to stream PubMed, to step Curation: 000462
- to stream PubMed, to step Checkpoint: 000438
Links to Exploration step
pubmed:12917971Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis.</title><author><name sortKey="Paramothayan, S" sort="Paramothayan, S" uniqKey="Paramothayan S" first="S" last="Paramothayan">S. Paramothayan</name><affiliation><nlm:affiliation>Respiratory Medicine, Kingston Hospital NHS Trust, Galsworthy Rd, Kingston Upon Thames, Surrey, UK, KT2 7QB.</nlm:affiliation><wicri:noCountry code="subField">KT2 7QB</wicri:noCountry></affiliation></author><author><name sortKey="Lasserson, T" sort="Lasserson, T" uniqKey="Lasserson T" first="T" last="Lasserson">T. Lasserson</name></author><author><name sortKey="Walters, E H" sort="Walters, E H" uniqKey="Walters E" first="E H" last="Walters">E H Walters</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12917971</idno><idno type="pmid">12917971</idno><idno type="doi">10.1002/14651858.CD003536</idno><idno type="wicri:Area/PubMed/Corpus">000462</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000462</idno><idno type="wicri:Area/PubMed/Curation">000462</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000462</idno><idno type="wicri:Area/PubMed/Checkpoint">000438</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000438</idno><idno type="wicri:Area/Ncbi/Merge">000036</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis.</title><author><name sortKey="Paramothayan, S" sort="Paramothayan, S" uniqKey="Paramothayan S" first="S" last="Paramothayan">S. Paramothayan</name><affiliation><nlm:affiliation>Respiratory Medicine, Kingston Hospital NHS Trust, Galsworthy Rd, Kingston Upon Thames, Surrey, UK, KT2 7QB.</nlm:affiliation><wicri:noCountry code="subField">KT2 7QB</wicri:noCountry></affiliation></author><author><name sortKey="Lasserson, T" sort="Lasserson, T" uniqKey="Lasserson T" first="T" last="Lasserson">T. Lasserson</name></author><author><name sortKey="Walters, E H" sort="Walters, E H" uniqKey="Walters E" first="E H" last="Walters">E H Walters</name></author></analytic><series><title level="j">The Cochrane database of systematic reviews</title><idno type="eISSN">1469-493X</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (adverse effects)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Chloroquine (therapeutic use)</term><term>Cyclosporine (therapeutic use)</term><term>Humans</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Methotrexate (therapeutic use)</term><term>Randomized Controlled Trials as Topic</term><term>Sarcoidosis, Pulmonary (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (effets indésirables)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Chloroquine (usage thérapeutique)</term><term>Ciclosporine (usage thérapeutique)</term><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term><term>Immunosuppresseurs (effets indésirables)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Méthotrexate (usage thérapeutique)</term><term>Sarcoïdose pulmonaire (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Chloroquine</term><term>Cyclosporine</term><term>Immunosuppressive Agents</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoidosis, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sarcoïdose pulmonaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Chloroquine</term><term>Ciclosporine</term><term>Immunosuppresseurs</term><term>Méthotrexate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immunosuppressive and cytotoxic agents have been used as both an alternative to oral corticosteroids, and as a means of maintaining a low dose of steroids in the treatment of pulmonary sarcoidosis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12917971</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Issue>3</Issue><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis.</ArticleTitle><Pagination><MedlinePgn>CD003536</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immunosuppressive and cytotoxic agents have been used as both an alternative to oral corticosteroids, and as a means of maintaining a low dose of steroids in the treatment of pulmonary sarcoidosis.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the efficacy of immunosuppressive and cytotoxic agents in the treatment of pulmonary sarcoidosis.</AbstractText><AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">The Cochrane Airways Group trials register was searched for possible randomised trials. Bibliographies were searched for other potentially relevant trials. Searches were current as of February 2001.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised controlled trials comparing an immunosuppressive or cytotoxic therapy with a control in patients with pulmonary sarcoidosis were included in the review.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two reviewers independently extracted data for entry in to the Review Manager statistical package (MetaView 4.1). Pharmaceutical companies and study investigators were contacted for unpublished trials.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Four studies were included in the review. Trials comparing methotrexate, chloroquine and cyclosporin A were identified. No data could be combined for a meta-analysis. Data on lung function, chest x-ray scores and dyspnoea were largely inconclusive. Adverse effects were associated with methotrexate, cyclosporin A and chloroquine. In one small study, methotrexate was associated with a steroid sparing effect after 12 months of therapy, but no difference was observed at 6 months.</AbstractText><AbstractText Label="REVIEWER'S CONCLUSIONS" NlmCategory="CONCLUSIONS">The current body of evidence supporting the use of immunosuppressive agents and cytotoxic therapies is limited. Side-effects associated with some of the therapies were severe.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paramothayan</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, Kingston Hospital NHS Trust, Galsworthy Rd, Kingston Upon Thames, Surrey, UK, KT2 7QB.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasserson</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber><NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Cochrane Database Syst Rev. 2006;(3):CD003536</RefSource><PMID Version="1">16856012</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017565" MajorTopicYN="N">Sarcoidosis, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>46</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12917971</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD003536</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Lasserson, T" sort="Lasserson, T" uniqKey="Lasserson T" first="T" last="Lasserson">T. Lasserson</name><name sortKey="Paramothayan, S" sort="Paramothayan, S" uniqKey="Paramothayan S" first="S" last="Paramothayan">S. Paramothayan</name><name sortKey="Walters, E H" sort="Walters, E H" uniqKey="Walters E" first="E H" last="Walters">E H Walters</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000036 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000036 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:12917971
|texte= Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:12917971" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |